Blog

  • Kolling awards unveiled

    Kolling awards unveiled

    We are pleased to announce the successful recipients of our annual Kolling Institute awards program.

    Launched in 2021, the program has been expanded to acknowledge a greater number of researchers and their individual contribution to the Kolling.

    The awards aim to recognise the many outstanding achievements across education, clinical practice and service, publications, research, as well as overall accomplishment.

    This year, seven researchers are being presented with awards across the following five categories:

    PhD impact (joint award winners)

    Dr Danielle Stone – Clinical Speech Pathologist, RNSH, and PhD candidate, Neuromuscular Imaging Research Lab

    Dr Michal Lubomski – Neurologist, RNSH and PhD Candidate, Neurogenetics Research

    Supervision impact (joint award winners)

    Associate Professor Sarah Glastras – Endocrinologist, RNSH and Postdoctoral Researcher, Renal Research Laboratory

    Dr Sumit Sahni – Senior Research Fellow, Bill Walsh Cancer Research Lab

    Best clinical output

    Dr Jillian Eyles – Physiotherapist, RNSH and SHPs Research Translation Fellow, Osteoarthritis Research

    Best EMCR basic science paper

    Dr Chia-chi Liu – Senior Research Fellow, Cardiac Membrane Biology Laboratory

    Best paper overall

    Dr Yandong Shen – Postdoctoral Researcher, Northern Blood Research Centre

    Kolling Institute Academic Director Professor Jim Elliott congratulated the researchers for their invaluable contribution over the past 12 months.

    “It’s encouraging that we have so many dynamic researchers working across the Kolling, and this impressive group has had an intrinsic role in our progress, impact and research success over the past year,” he said.

    “Each of these award winners is driving substantial improvements in their individual areas of expertise, and I’m pleased that through the Kolling awards program we’re able to direct the spotlight to their significant achievements.”

  • International recognition for remarkable Kolling researcher

    International recognition for remarkable Kolling researcher

    We would like to congratulate Professor Carol Pollock who has received a highly prestigious award for her extraordinary commitment to research.

    The International Society of Nephrology has announced Professor Pollock is the 2023 recipient of the Alfred Newton Richards award for outstanding research in the field of nephrology.

    Carol has welcomed the news.

    “I am extremely honoured to be recognised by the ISN for the research my team and I have done over many years,” she said.

    “Prior recipients of the Alfred Newton Richards Award are exceptional and I am proud to be included in this relatively small group of nephrology researchers internationally.”

    As a renal medicine specialist and internationally respected academic, Professor Pollock has had a remarkable career as a clinician, researcher, lecturer, mentor and advocate.

    Carol has published over 440 papers in clinical medicine and basic science. She has over 32,000 citations and is an inaugural Fellow of the Australian Academy of Health and Medical Sciences.

    Carol has had an extensive range of health leadership roles, and is currently the Chair of Kidney Health Australia, Chair of the NSW Bureau of Health Information and Deputy Chair of the Australian Organ, Tissue and Transplant Authority. She was chair of the NSLHD Board from 2010-2016.

    Carol is on several industry boards and is an ambassador of Business Events Sydney.

    Her dedication to her clinical and research endeavours have been recognised with many accolades, including a ministerial award for excellence in cardiovascular research and a Vice Chancellors award for research supervision from the University of Sydney.

    In 2021, Carol received the Haiyan Wang Award which recognises individuals who have made substantial contributions to the clinical or translational science and development of nephrology service and education in the Asia Pacific Region.

    In that year, Carol was also appointed an officer of the Order of Australia (AO) for her distinguished service to medical research, education and science, nephrology and clinical practice. 

  • Philanthropic support helping women with gestational diabetes and their babies

    Philanthropic support helping women with gestational diabetes and their babies

    Generous funding provided through the Douglas and Lola Douglas scholarship is strengthening evidence around the long term impacts on children born to mothers with obesity and gestational diabetes.

    Endocrinologist and Kolling Institute researcher Dr Tessa Weir has been able to continue her valuable research as a result of being awarded the scholarship.

    “I am incredibly grateful for the support provided through the Douglas and Lola Douglas scholarship,” she said.

    “It has meant I’ve been able to pursue my postgraduate studies and support improvements in the care of women with obesity and gestational diabetes, and their babies.

    “My hope is to fill the gaps in evidence and generate guidelines and policy to extend prenatal and perinatal obstetric care, particularly for women managing these health challenges.

    “Our research will involve a systematic review to detail how maternal obesity and gestational diabetes directly affects neonatal outcomes. We will also be using new artificial intelligence techniques to develop a personalised risk predictive tool for perinatal outcomes.

    “This will also consider the timing of births, with early births linked to many adverse impacts such as developmental delays.”

    Dr Weir said this is such an important field of research, with maternal obesity and gestational diabetes contributing to significant, long-term health challenges for unborn children.

    “We know from earlier research by fellow Kolling researchers Associate Professor Sarah Glastras and Professor Carol Pollock that these maternal factors can influence foetal programming, and alter an unborn child’s future metabolic risk. This in turn increases the likelihood of ongoing weight issues.

    “The prevalence of child and adolescent obesity is increasing, with an alarming 25 per cent of children in Australia over the healthy weight range.

    “Childhood obesity is associated with an increased risk of developing cardiovascular disease, chronic kidney disease, diabetes and psychological conditions.

    “All of these issues can have a life-long impact, compromising quality and even length of life, so it’s tremendously important we drive research progress in this area and broadly improve the quality of care provided to women and their babies.

    “Overall, this scholarship is not only helping me complete my PhD studies, and broaden my experience as a clinician-researcher, it will also hopefully improve the future health of countless children born to women with gestational diabetes and obesity.”

  • Transforming treatments for those with diabetes

    Transforming treatments for those with diabetes

    Kolling researcher and Royal North Shore Hospital endocrinologist Associate Professor Sarah Glastras will have a key role in a national effort to improve long-term outcomes for those with diabetes.

    The initiative has brought dozens of experts from across the country together under the banner of the Australian Centre for Accelerating Diabetes Innovations Research.

    International collaborators will also be involved, providing crucial research data and supporting advances in the delivery of care.

    The centre, which has been made possible with Federal Government funding, will drive improvements in the care of those with diabetes from diagnosis through to its devastating complications.

    Importantly, the program will aim to support Indigenous and non-Indigenous Australians, addressing inequities in care and increasing life expectancy for all Australians. Targeted programs will ensure equal access to new products and clinical trials regardless of cultural backgrounds or remote locations.

    Associate Professor Glastras is the training lead for the project, and will oversee the program along with a team of training advisors from each state and territory.

    “This is a tremendously exciting program bringing the brightest minds in the country together to deliver new models of care for the diagnosis, prevention and treatment of diabetes and its complications,” she said.

    “I’m thrilled to have been appointed the ACADI training lead and I look forward to providing much needed support to trainees, especially in the areas of research translation – making sure that the research that we do leads to important benefits and outcomes for our patients.

    “The ACADI training program will leverage the expertise from the medical and research community, government and related agencies, commercial partners and people with diabetes.”

    The national initiative has identified three priority areas, including a focus on diabetic kidney disease, diabetic foot syndrome and complications from hyperglycaemic hyperosmolar syndrome.

    A third of people with diabetes develop diabetic kidney disease, which is the leading cause of end-stage kidney disease, and a major risk factor for cardiovascular disease and premature death.

    “Sadly, current interventions only slow the progression of diabetic kidney disease.

    “It’s anticipated there will be an increasing demand for kidney replacement therapy with our ageing population and an increasing prevalence of diabetes in younger age groups.

    “We are very hopeful that this national initiative will accelerate innovations to improve the lives of people with the disease and at risk of developing the condition.

    “Our research will focus on the early identification of people at risk, improvements in diagnosis, prognosis and management. We hope that this collaborative approach will deliver real improvements in the care offered to all communities.”

    In further encouraging news, Sydney Health Partners has established a Diabetes and Obesity Clinical Academic Group. Associate Professor Glastras will be part of this new collaborative group which will explore research gaps in obesity, pre-diabetes and diabetes treatment.

  • Our research expertise recognised with multi-million dollar grants

    Our research expertise recognised with multi-million dollar grants

    We would like to congratulate Professors Carol Pollock and Gemma Figtree who have received significant National Health and Medical Research Council Investigator Grants.

    Despite a tremendously competitive field, both clinician/researchers have been awarded $2 million to progress their world-leading research and improve long-term patient outcomes.

    The announcement highlights the experience and expertise at the Kolling Institute, with Professors Pollock and Figtree joint leaders of our Cardiovascular and Renal Priority Research Area.

    Professor Figtree’s research will investigate innovative solutions to reduce heart attacks for those without the typical risk factors.

    Professor Figtree, an interventional cardiologist at Royal North Shore Hospital, said approximately one-quarter of first-time heart attack patients do not have any of the typical risk factors of coronary artery disease, and yet they have developed what is regarded as silent coronary artery disease without any symptoms.

    Gemma and her team will use this group to extend their understanding of the disease and identify markers relevant to all patients at risk of a heart attack.

    Her program will drive the discovery of new biomarkers for the early detection and treatment of coronary artery disease. This will lead to improved knowledge and health outcomes, and importantly, earlier diagnosis and treatment of the disease.

    “I am enormously grateful to the NHMRC for this support. It will help my team follow exciting leads towards clinical translation, and help develop a new way of detecting coronary artery disease and preventing heart attacks,” she said.

    Professor Carol Pollock’s program of research will work to reduce the personal and societal impact of kidney disease.

    Carol is a renal medicine specialist at Royal North Shore Hospital and an internationally respected academic at the Kolling Institute.

    Chronic kidney disease currently affects over 13 per cent of the global population and 10 per cent of Australians. End-stage kidney disease is escalating and directly costing the Australian economy around $1.8 billion a year.

    Professor Pollock says despite our treatment strategies, a progressive loss of renal function is inevitable.

    Our program will involve three main components, including an assessment of new strategies to prevent or slow the development of kidney disease for which we currently have some positive preliminary data. These include ibody therapeutics, and the delivery of mesenchymal stem cells.

    We will also expand our program promoting the regenerative capacity of kidney fibroblasts, and finally, we will thoroughly analyse the models involved kidney disease that spontaneously recover from kidney injury compared with the models that progress to irreversible fibrosis.

    “I’m really thrilled to have secured this funding to undertake our work and develop our research which we hope will have transformational benefits for patients with kidney disease,” she said.

    “While early-stage research requires several years to translate to clinical benefit, we are well placed at the Kolling to speed-up improvements in patient care.

    “For a clinician researcher, the Kolling Institute, a partnership between the University of Sydney and the Northern Sydney Local Health District, provides the ideal environment to take basic research to clinical trials.

    “Our Renal Research Laboratory has researchers from diverse professional backgrounds and this will facilitate the successful delivery of the research.

    “Importantly, we are also well supported by partners in the biotech and pharma industries to accelerate our research into practice.

    “The security that five years funding brings is welcomed by my exceptional scientific staff and I would also like to acknowledge the philanthropic support we have received.

    “I fully recognise that without seed funding from philanthropists this funding would not have occurred.

    “I am grateful for the untied funding that has allowed me and my laboratory to develop preliminary data, which has in turn paved the way for these funds.

    “We look forward to progressing our work and sharing some amazing results over the next five years.” 

  • Encouraging news for those with chronic kidney disease

    Encouraging news for those with chronic kidney disease

    Improved accessibility to a treatment for kidney disease has been welcomed by Kolling Institute researcher and Royal North Shore Hospital clinician Professor Carol Pollock.

    Forxiga (dapagliflozin), an oral medicine which can help slow the progression of proteinuric chronic kidney disease, has now been listed on the Pharmaceutical Benefits Scheme.

    The listing aims to help those with the condition by slowing the progression to kidney transplantation and dialysis.

    Professor Pollock, who is also Chair of Kidney Health Australia, said the PBS listing should give clinicians more options to help manage the condition.

    “Patients diagnosed with proteinuric chronic kidney disease currently have few treatment avenues,” she said.

    “The priority is to slow the progression to dialysis and kidney transplantation, so it’s encouraging this option will now be available.

    “This medicine has been used to manage type 2 diabetes and heart failure, and it is pleasing to see that it will be an accessible option supporting the treatment of patients diagnosed with this type of kidney disease.”

    Chronic kidney disease is a serious, progressive condition defined by decreased kidney function. It is often associated with an increased risk of heart disease or stroke.

    The recent Australian Institute of Health and Welfare Chronic Kidney Disease report found that the condition contributed to about 18,000 deaths in Australia in 2020.

    “It is essential that Australians living with chronic kidney disease have access to innovative treatments so they can better manage their condition,” Chris Forbes, CEO of Kidney Health Australia, said.

    “More broadly, we need to encourage Australians to understand if they are at risk of chronic kidney disease and if so, to speak with their GP to seek an early diagnosis.

    “An early diagnosis together with education, treatment and support will improve the health of the many Australians affected by the disease.” 

  • New Academic Director shares vision for research success

    New Academic Director shares vision for research success

    Ambitious leadership, functional wellbeing and a passion for collaboration

    An international healthcare destination celebrated for its collaborative spirits and dedication to human health and wellbeing. This is Professor Jim Elliott’s vision for how the collaboration between the Kolling Institute, the Faculty of Medicine and Health and the Northern Sydney Local Health District will evolve.

    Highly respected in the global research community, Professor Elliott was recently appointed the Kolling Institute’s Academic Director. His past careers in professional baseball, physiotherapy and research academia have offered Jim a wealth of wisdom to draw from and have shaped his positive, enthusiastic and empathetic mindset. When listing the advice he has picked up along the way, he includes, “Do simple better” and “Be present, not perfect.”

    Common goals
    In his new role, Jim will work towards the shared strategic goals of the Kolling, the Faculty of Medicine and Health and the NSLHD. These goals also align with the Northern Health Precinct model, leveraging the strength of joint-venture partners and enabling all to reach shared goals. Jim understands that “we share a common vision to support world-leading translational research, increase our research impact and consistently improve health outcomes.”

    In his new role, Jim looks forward to working collaboratively “inside and outside the building” to address and report against the growth and sustainability of the Kolling Institute.

    From his days as a professional baseballer, Jim applies the advice, “Don’t give folks an opportunity to misquote you in the press.” He believes that having a clear and consistent media and communications strategy is crucial for internal and external facing messaging, which also supports the recruitment and retainment of new high-flying faculty, clinical staff and students.

    Together, we will determine how our impact will be measured, recorded, and shared through a strategic and wide-reaching communications plan. Our approach will work towards ensuring the Kolling Institute is an international healthcare destination – one that the NSLHD and the faculty can be proud of.

    Jim’s experience as a Professor of Allied Health makes it feel like a natural fit for him when it comes to putting the Northern Health Precinct’s key theme of Functional Wellbeing into action. Wellbeing represents a complex combination of physical, mental, emotional and social health and is strongly linked to happiness and life satisfaction. Additionally, allied health professionals offer a broad range of diagnostic, technical, therapeutic and direct health services to improve the health and wellbeing of the patients they work with.

    Jim’s vision
    Jim’s respect for interdisciplinary collaboration has grown following a career as a research academic trained as a physiotherapist.

    In short, our successes are a sum of all the parts and that goes a long way towards translation of research into clinical practice where it can positively influence patient-outcomes on a patient-by-patient basis. This requires trusting and productive collaboration between our medical, nursing and allied health colleagues.

    Jim highlights that traditional models of healthcare are delivered and evaluated in isolation, where patients are expected to seek individual services with little or no collaboration between healthcare providers. He recognises that the current health professional educational models, which operate the same way, as unintentional contributors to the development and maintenance of siloed areas of health. They reinforce the lack of valuable interdisciplinary collaboration between staff and students from various professions.

    Jim hopes to meet the need for developing new models of student and staff interaction, education, clinician research pathways and patient service delivery through creating best-practice interdisciplinary student placements. These models will aim to enhance functional wellbeing with the ability to be delivered across a range of settings and populations.

    He predicts that by leveraging the strengths, resources and expertise of the Kolling Institute, the Faculty of Medicine and Health and the NSLHD, we will be well placed to expand our research success.

    This approach will help position us as global leaders in health and medicine, and ensure we deliver research outcomes that ultimately improve the care our community members receive.

    The innovative and diverse nature of this partnership delivers best-practice interdisciplinary models of education and care-pathways by which the NSLHD, the University, NSW TAFE and our local community members can work together.

    A passionate HDR Supervisor
    Among a remarkable list of achievements, Jim has directly improved health practices around neck pain, broadened our understanding of whiplash injuries and embraced cutting-edge technology to progress research in the complex trauma and pain fields. Jim remembers when a clinical mentor of his quoted renowned nurse, Margo McCaffery, ‘Pain is whatever the experiencing person says it is, existing whenever and wherever the experiencing person says it does’. “To me, if we are to believe McCaffery’s statement (and I do), then it means the patient is the closest thing to a gold-standard measure of pain there is,” he adds.

    Jim’s career in research academia and collaborative spirit is influenced by the African proverb, “If you want to go fast, go alone. If you want to go far, go together.” When reminiscing on his favourite memory since joining the University, he recalls when his first PhD student, Dr Danielle Stone, Speech Pathologist at Royal North Shore Hospital, enrolled in 2019. “In the blink of an eye, she received word she had been recommended for the award of the degree of Doctor of Philosophy, WITHOUT FURTHER CONDITIONS!”

    It was very pleasing to witness Danielle’s growth and development in this interdisciplinary environment and the respect she gained from her team. It is also noteworthy, that Danielle completed her PhD studies in the university timeline while working clinically as a speech pathologist at Royal North Shore Hospital and is a mum of three young children.

    Danielle’s thesis, Dysphagia, Dysphonia, and Laryngeal Hypersensitivity following Whiplash, brought together an international team of leading research academics from Speech Pathology, Physiotherapy, Magnetic Resonance Physics, Genetics and Molecular Biology, and Psychology.

    “A true interdisciplinary collaborative,” as Jim hails it, making it only fitting that he respectfully quotes Ginger Rogers as some of the most important advice he’s learnt, “I did everything Fred Astaire did, backwards and in heels.”

  • Researchers develop test to identify the severity of kidney disease

    Researchers develop test to identify the severity of kidney disease

    We may soon have a safer approach to diagnosing and measuring the progression of chronic kidney disease following new research by the team from the Kolling Institute’s Renal Research Laboratory.

    The condition is a global health issue, which now affects more than 13 per cent of the worldwide population.

    Chronic kidney disease is a progressive disease that leads to end-stage kidney failure, which is fatal without dialysis or a kidney transplant.

    Currently there are tests to detect advanced stages of the disease, but early detection is not possible.

    Biopsies are performed to confirm a diagnosis of chronic kidney disease, but this approach brings with it inherent risks such as bleeding, pain and hospitalisation.

    Encouragingly, researchers from the Kolling Institute and the University of New South Wales have now developed biomedical technology to provide accurate information around early diagnosis and prognosis, without the risks of an invasive biopsy procedure.

    Head of the Kolling’s Renal Research Laboratory Professor Carol Pollock said this exciting new technology provides clear information about kidney pathology by examining kidney cells in urine.

    “Having the ability to diagnose patients with a simple urine test represents a significant step forward for those with chronic kidney disease,” she said.

    “Importantly, this enables early intervention and effective management.”

    Project co-lead Associate Professor Sonia Saad said that being able to assess kidney pathology in a non-invasive way brings a host of benefits.

    “It will enable clinicians to examine the effects of new drugs on the kidney and monitor kidney pathology over time. This will provide valuable information on the effectiveness of treatments.”

    PhD student Dr Henry Wu has welcomed the chance to be involved in the project.

    “It’s been rewarding to have been part of the development of this important new technology. We would like to see it applied broadly across clinical practice given the health and economic benefits of this approach,” he said.

    The study is being led by Professor Pollock and Associate Professor Saad from the University of Sydney in collaboration with Professor Ewa Goldys and her team from the University of New South Wales.

  • Link between obesity severity and adverse outcomes for pregnant women and their babies

    Link between obesity severity and adverse outcomes for pregnant women and their babies

    There are calls for a greater focus on weight management following new research defining the relationship between obesity and pregnancy-related complications for mother and baby.

    The study follows an increase in obesity levels globally as well as a rise in prevalence during pregnancy. Today, more than 20 per cent of Australian women have obesity at the time of conception.

    Kolling Institute and University of Sydney researcher and Royal North Shore Hospital Endocrinologist Associate Professor Sarah Glastras said we know that obesity in pregnancy increases the risk of the mother developing gestational diabetes, gestational hypertension or high blood pressure, and pre-eclampsia. There’s also a higher risk of stillbirth as well as a caesarean section delivery.

    “Women with obesity are more likely to deliver a baby with congenital abnormalities, respiratory distress syndrome and have a large baby,” she said.

    “Our research has now given us a much clearer picture of the direct link between the severity of obesity and the risk of adverse impacts for both the mother and her baby.”

    Three classes of obesity were identified based on body mass index with class one assessing women with the lowest severity of obesity.

    • The research found 21 per cent of women with class I obesity developed gestational diabetes, compared with 28 per cent with class III.
    • Women with class I obesity had half the risk of developing pre-eclampsia compared class III. (2.8% versus 6.2%).
    • There was an increased risk of caesarean delivery, with a 40 per cent risk in class I, a 45 per cent risk in class II and 54 per cent in class III. This compared with the national average of 33 per cent.
    • 26 per cent of women with class I obesity had a large baby compared with 33 per cent in class III.
    • Stillbirth and birth defects were more common in women with more severe obesity.

    “Our study highlights the importance of weight management in women of child-bearing age, not just during pregnancy, but also at time of conception,” said Associate Professor Glastras.

    “Encouragingly, we also demonstrated that with good obstetric care, we can mitigate some of the risks associated with obesity in pregnancy.

    “Our research not only provides individuals with an incentive to manage their own weight, but also offers health providers and policy-makers more evidence to support pre-conception weight management initiatives.”

  • The Kolling’s up and coming talent recognised

    The Kolling’s up and coming talent recognised

    Acting Executive Director Professor Jim Elliott has announced the winners of the inaugural Kolling Institute Emerging Leader Awards, saying there’s an inspiring depth of expertise throughout the institute.

    Professor Elliott said the new awards recognise our young leaders across our basic and translational research, and were initiated by the institute’s Workforce and Culture Enabler Committee.

    “Four awards are being presented in 2021 and I’m delighted to announce the successful applicants,” he said.

    “In the EL1 category, Dr Qinghua Cao, a postdoctoral research associate with the Renal Research Team and Dr Lisa Kouladjian O’Donnell, a research fellow with the Laboratory of Ageing and Pharmacology, have taken out the awards.

    “While in the EL2 category, Dr John Mach a post-doctoral research fellow from the Laboratory of Ageing and Pharmacology, and Dr Sumit Sahni, a research fellow with the Bill Walsh Translational Cancer Research Laboratory have been presented with awards.

    “I would like to congratulate this year’s award winners for their outstanding track record and tremendous efforts to drive our research progress and improve the care our community receives.

    “I understand the selection committee was impressed by the quality of the submissions, the scientific rigour and the commitment to research excellence.

    “Each award recipient has demonstrated a strong focus with their individual research, a collaborative approach and a commitment to improving a significant health challenge.

    “I would like to commend this year’s successful recipients, and mention that we are already looking to expand the awards program next year so that a larger number of researchers can be recognised.

    “These new awards are one key part of a broader approach to ensure our day-to-day core business fosters a supportive and collaborative working culture.” 

NSWGOV logo